Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - vankomicinklorid - kapsula, tvrda - urbroj: svaka kapsula sadrži 125 mg vankomicinklorida što odgovara 125 000 iu vankomicina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - vankomicinklorid - kapsula, tvrda - urbroj: svaka kapsula sadrži 250 mg vankomicinklorida što odgovara 250 000 iu vankomicina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

reckitt benckiser d.o.o., ulica grada vukovara 269d, zagreb, hrvatska - ibuprofen - tableta s produljenim oslobađanjem - urbroj: jedna tableta sadrži 300 mg ibuprofena

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - metforminklorid - tableta s produljenim oslobađanjem - urbroj: jedna tableta s produljenim oslobađanjem sadrži 1000 mg metforminklorida, što odgovara 780 mg metformina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - metforminklorid - tableta s produljenim oslobađanjem - urbroj: jedna tableta s produljenim oslobađanjem sadrži 500 mg metforminklorida, što odgovara 390 mg metformina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - metforminklorid - tableta s produljenim oslobađanjem - urbroj: jedna tableta s produljenim oslobađanjem sadrži 750 mg metforminklorida, što odgovara 585 mg metformina

Europska Unija - hrvatski - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatid - osteoporosis; osteoporosis, postmenopausal - homeostaza kalcija - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

elanco gmbh - valnemulin - Противоинфекционные za sistemsku primjenu - pigs; rabbits - pigsthe liječenje i prevenciju dizenterija svinja. liječenje kliničkih znakova svinjske proliferativne enteropatije (ileitis). prevencija kliničkih znakova svinjske kolonije spirochaetosis (kolitis) kada je bolest dijagnosticirana u stadu. liječenje i prevencija svinjske enzootske upale pluća. po preporučenoj dozi od 10-12 mg / kg tjelesne težine plućnih lezija i gubitka težine smanjuju se, ali infekcija mycoplasma hyopneumoniae nije eliminirana. rabbitsreduction smrtnosti tijekom epidemije эпизоотическая zec энтеропатия (ЭРД). liječenje treba započeti rano u izbijanju, kada je klincu dijagnosticiran prvi zec.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.